Nimesulide Capsules

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects. Its mechanism of action is not yet fully understood, but it may be mainly related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.

The main ingredient of this product is nimesulide, and its chemical name is: N-[4-nitro-2-phenoxyphenyl] methanesulfonamide.

This product is a capsule, and the contents are light yellow powder.

This product is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic effects. Its mechanism of action is not yet fully understood, but it may be mainly related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.

Oral administration: 0.05-0.1g at a time, twice a day, after meals. The maximum single dose should not exceed 100mg, and the course of treatment should not exceed 15 days. It is recommended to use the minimum effective dose and the shortest course of treatment to reduce the occurrence of adverse drug reactions.

This product has fewer side effects. Common side effects are heartburn, stomach pain and gastrointestinal disorders, but the symptoms are mild and short-lived, and rarely require interruption of treatment. In rare cases, patients develop allergic rashes after taking it. Even if the above symptoms do not occur when using nimesulide, it should be noted that this product, like other non-steroidal anti-inflammatory drugs, may cause dizziness, drowsiness, gastric ulcers or gastrointestinal bleeding and Stevens-Johnson syndrome.

1. Patients who are allergic to this product, acetylsalicylic acid or other non-steroidal drugs are contraindicated. 2. Patients with active gastrointestinal bleeding or active peptic ulcer are contraindicated. 3. Patients with severe liver dysfunction and severe renal dysfunction (creatinine clearance rate 30 ml/min) are contraindicated.

Precautions for children: Children under 12 years of age are prohibited from using this product. Precautions for pregnancy and lactation: Women who are 7 to 9 months pregnant are prohibited from using this product. Like other nonsteroidal anti-inflammatory drugs, this product is not recommended for women who are preparing to become pregnant. Like other nonsteroidal anti-inflammatory drugs, nimesulide can cause ductus arteriosus insufficiency, pulmonary hypertension, oliguria, oligohydramnios, increased risk of bleeding, uterine atony, and edema of the extremities by inhibiting the synthesis of prostaglandins. There are independent reports of renal failure in newborns caused by women taking this product in late pregnancy. Studies conducted on rabbits have shown that this product has atypical reproductive toxicity, and there is no sufficient data on the use of this product in pregnant women for reference. Therefore, the potential risk of this product to humans is unclear, and this product is not recommended for use in the first 6 months of pregnancy. It is unclear whether nimesulide can be secreted into breast milk during lactation. This product is prohibited during lactation. Precautions for the elderly: There is no need to reduce the daily dose for the elderly. However, since elderly patients are particularly prone to adverse reactions to nonsteroidal anti-inflammatory drugs, including gastrointestinal bleeding and perforation, renal impairment, cardiac impairment, and liver impairment, it is recommended that elderly patients be given correct clinical guidance and that clinical manifestations and changes in laboratory indicators that indicate organ damage in elderly patients be closely observed.

Due to the high plasma protein binding rate of this product, it may displace other protein-bound drugs. Furosemide affects the absorption of nimesulide, causing the AUC value of nimesulide to decrease by about 25%; fenofibrate, tolbutamide, and salicylic acid can displace nimesulide from plasma proteins, while furosemide, glibenclamide, and therapeutic doses of warfarin have no effect on the binding rate of nimesulide to proteins.

Seal and store in a dry place. The validity period is tentatively one year.

0.1g

24 months

Hunan Weite Pharmaceutical Co., Ltd.

• Founded in:

  2003-03-31

• Address:

  No. 97, Kangping Road, Liuyang Economic and Technological Development Zone

• Tax NO.:

  914301817406413726

• Registered Funds:

  10 million yuan

• Website:

  Log in to view

• Email:

  Log in to view